Argen-X (ARGX)

261.40
+4.10(+1.59%)
  • Volume:
    11,262
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    257.60 - 264.10
  • Type:Equity
  • Market:Belgium
  • ISIN:NL0010832176

ARGX Overview

Prev. Close
257.3
Day's Range
257.6-264.1
Revenue
570.45M
Open
259.9
52 wk Range
201.4-314.6
EPS
-6.2
Volume
11,262
Market Cap
13.35B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
57,276
P/E Ratio
-
Beta
0.57
1-Year Change
7.84%
Shares Outstanding
51,515,021
Next Earnings Date
03 Mar 2022
What is your sentiment on Argen-X?
or
Vote to see community's results!

Argen-X Company Profile

Employees
336
Market
Belgium

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyBuy
Technical IndicatorsStrong BuyStrong BuyBuySellStrong Buy
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Buy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.